Medical technology company BioTelemetry and its heart rate monitoring subsidiary CardioNet agreed to pay more than $44.8 million to settle allegations they violated U.S. federal health laws by improperly billing Medicare and other federal programs for heart monitoring and cardiac test analyses performed by a company in India.
Federal law requires services for patients of federal health programs, like Medicare, be provided within the United States to be reimbursed.
